» Articles » PMID: 32420260

Not All Adrenal Incidentalomas Require Biochemical Testing to Exclude Pheochromocytoma: Mayo Clinic Experience and a Meta-analysis

Overview
Journal Gland Surg
Specialty Endocrinology
Date 2020 May 19
PMID 32420260
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Excluding a pheochromocytoma is important when a patient presents with an incidentally discovered adrenal mass. However, biochemical testing for pheochromocytoma can be cumbersome, time consuming, or falsely positive. Our objective was to determine if unenhanced computed tomography (CT) imaging alone can be used to rule out pheochromocytoma.

Methods: We performed a retrospective study of all patients with a pathologically confirmed pheochromocytoma and unenhanced CT imaging who were treated at the Mayo Clinic between 1998 and 2016. Additionally, we performed a systematic review and meta-analysis of original studies published after 2005 with patients who had adrenal masses, more than 10 patients with pheochromocytomas, and reported attenuation on unenhanced CT imaging in Hounsfield units (HU).

Results: In the Mayo cohort, we identified 186 patients and 199 pheochromocytomas with unenhanced CT imaging. The mean unenhanced CT attenuation was 35±9 HU (range, 15-62), and only 15 tumors had attenuation ≤20 HU. The systematic review identified 26 studies (1,217 tumors), and 23 studies provided a mean unenhanced CT attenuation. The overall mean unenhanced CT attenuation across the studies was 35.6 HU (95% CI, 22.0-49.1 HU). A cutoff of >10 HU had a 100% sensitivity (95% CI, 1.00-1.00) for pheochromocytoma with low heterogeneity between the 21 qualified studies (I=0%). Sensitivity for pheochromocytoma was 100% and 99% for an unenhanced CT attenuation cutoff of >15 and >20 HU.

Conclusions: Biochemical testing may not be required to exclude pheochromocytoma if an incidental adrenal mass has low attenuation (<10 HU) on unenhanced CT images.

Citing Articles

A Rare Case of Metastatic Adrenal Melanoma.

Khan R, Kahlon S, Maragh J, Kimble A, Gupta S Cureus. 2024; 16(7):e64182.

PMID: 39119371 PMC: 11309760. DOI: 10.7759/cureus.64182.


Imaging of Pheochromocytomas and Paragangliomas.

Timmers H, Taieb D, Pacak K, Lenders J Endocr Rev. 2024; 45(3):414-434.

PMID: 38206185 PMC: 11074798. DOI: 10.1210/endrev/bnae001.


A Laboratory Medicine Perspective on the Investigation of Phaeochromocytoma and Paraganglioma.

Boot C Diagnostics (Basel). 2023; 13(18).

PMID: 37761307 PMC: 10529273. DOI: 10.3390/diagnostics13182940.


Pheochromocytoma: Clinical Experience From a Single Tertiary Care Center in India.

Lu C, Naushad A, P R M, Kalra P, Selvan C, Y P G Cureus. 2023; 15(7):e41671.

PMID: 37575861 PMC: 10412895. DOI: 10.7759/cureus.41671.


Canadian Urological Association guideline: Diagnosis, management, and followup of the incidentally discovered adrenal mass.

Rowe N, Kumar R, Schieda N, Siddiqi F, McGregor T, McAlpine K Can Urol Assoc J. 2023; 17(2):12-24.

PMID: 36849113 PMC: 9970641. DOI: 10.5489/cuaj.8248.


References
1.
Zawadzka-Leska S, Radziszewski M, Malec K, Stadnik A, Ambroziak U . PREDICTIVE VALUE OF CHROMOGRANIN A IN A DIAGNOSIS TOWARDS PHEOCHROMOCYTOMA IN ADRENAL INCIDENTALOMA. Acta Endocrinol (Buchar). 2019; 12(4):437-442. PMC: 6535251. DOI: 10.4183/aeb.2016.437. View

2.
Kim D, Yoon S, Kim S, Kang E, Kwon H . Assessment of clinical and radiologic differences between small and large adrenal pheochromocytomas. Clin Imaging. 2017; 43:153-157. DOI: 10.1016/j.clinimag.2017.03.002. View

3.
Patel J, Davenport M, Cohan R, Caoili E . Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma?. AJR Am J Roentgenol. 2013; 201(1):122-7. DOI: 10.2214/AJR.12.9620. View

4.
Schalin-Jantti C, Raade M, Hamalainen E, Sane T . A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion. Endocrinol Metab (Seoul). 2015; 30(4):481-7. PMC: 4722402. DOI: 10.3803/EnM.2015.30.4.481. View

5.
Buitenwerf E, Korteweg T, Visser A, Haag C, Feelders R, Timmers H . Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J Endocrinol. 2018; 178(5):431-437. DOI: 10.1530/EJE-18-0006. View